1-877-439-2744 Motherisk Helpline
1-800-436-8477 Morning Sickness
1-877-327-4636 Alcohol and Substance
1-866-937-7678 Exercise in Pregnancy
1-888-246-5840 HIV and HIV Treatment
416-813-6780 Motherisk Helpline
Pregnancy & Breastfeeding Resources
Current Studies at Motherisk
The Safety of Diclectin in Breastfeeding
Neurodevelopment of Children Exposed in-Utero to Chemotherapy for Maternal Breast Cancer (Dr. I Nulman)
Diclegis Surveillance Program Study
Diclectin Surveillance Program Study
Study seeks women between 4 and 12 weeks in their pregnancy with morning sickness (NVP)
Pregnancy in Women with Multiple Sclerosis
Alcohol Use during Pregnancy
Lamisil in Pregnancy
Meridia in Pregnancy
Autoimmune Diseases in Pregnancy Project
Psychotropic drugs: Psychotropic General
American Journal of Obstetrics & Gynecology. 2003; 189:1810-1811.
Pinto N and Koren G. Research on maternal and fetal safety after exposure to antidepressants in utero.[comment].
[Review] [21 refs] Journal of Psychiatry & Neuroscience. 22(3):192-6, 1997 May.
Loebstein R, Koren G:Pregnancy outcome and neurodevelopment of children exposed in utero to psychoactive drugs: the Motherisk experience.
New England Journal of Medicine. 336(4):258-62, 1997 Jan 23.
Nulman I, Rovet J, Stewart DE, Wolpin J, Gardner HA, Theis JG, KulinN, Koren G: Neurodevelopment of children exposed in utero to antidepressant drugs